AzTrials
AzTrials

Research institution

Second Affiliated Hospital of Guangzhou Medical University Clinical Trials

Studies where Second Affiliated Hospital of Guangzhou Medical University is the lead sponsor: what is enrolling now, by phase, condition and country.

73 registered studies

In numbers

Open to volunteers
43
Active
43
With results posted
0
All registered
73

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 43
  • Hepatocellular Carcinoma Non-resectable

    Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

    • Recruiting
    • Age: 18 to 75 years
    • Phase 2

    This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX…

    Trial name
    NCT06904183
    Testing
    LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
    Where
    China
    Volunteers
    320 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06904183
  • Dravet Syndrome (DS)

    A Study to Evaluate the Safety and Pharmacokinetics of RC001 in Children With Dravet Syndrome

    • Recruiting
    • Age: 2 to 18 years
    • Early Phase 1
    • Injection or infusion

    This is an open-label, single-center study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of intrathecal RC001 in patients with Dravet syndrome aged 2 to 18 years.

    Trial name
    NCT07675746
    Testing
    RC001 injection-Dose Escalation Cohort, RC001 injection-Fixed Dose Cohort
    Where
    China
    Volunteers
    8 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT07675746
  • Hepatocellular Carcinoma

    Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 2
    • Injection or infusion

    This is a prospective, open-label, single-arm, investigator-initiated study designed to evaluate the safety and efficacy of NRT6003 Injection, a yttrium-90 carbon microsphere product, administered by selective internal radiation…

    Trial name
    NCT07657273
    Testing
    NRT6003 Injection
    Where
    China
    Volunteers
    20 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT07657273
  • Sepsis, Ivabradine

    Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

    • Recruiting
    • Age: 18 years and older
    • Phase 4

    Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of adequate volume resuscitation to correct hypovolemia and vasopressor medication to correct hypotension.

    Conditions
    Sepsis, Ivabradine, Hemodynamics, Heart Rate Control
    Trial name
    NCT05882708
    Testing
    Ivabradine
    Where
    3 sites in China
    Volunteers
    172 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT05882708
  • Type 2 Diabetes

    Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

    • Recruiting
    • Age: 18 to 65 years
    • Phase 1/2

    This study is a multicenter, randomized, controlled study. A sample size of 240 cases is proposed to be included. The inclusion criteria are: (1) patients with newly diagnosed type 2 diabetes; (2) age between 18 and 65 years old…

    Trial name
    TRED (NCT07374328)
    Testing
    Semaglutide (1 Mg Dose), Sitagliptin (DPP4 inhibitor)
    Where
    China
    Volunteers
    240 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? TRED
  • Epilepsy, Status Epilepticus

    Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus

    • Not yet recruiting
    • Age: 4 to 60 years
    • Observational study

    Status epilepticus (SE) is an acute and critical form of neurological and systemic diseases involving multiple clinical disciplines, with an annual incidence of (20-73) per 100,000 people and a clinical case fatality rate of 20%.

    Trial name
    NCT06966830
    Testing
    Lacosamide (LCM)
    Where
    China
    Volunteers
    100 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06966830
  • Hepatocellular Carcinoma Non-resectable

    Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

    • Recruiting
    • Age: 18 to 75 years
    • Phase 2

    This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization…

    Trial name
    NCT06904196
    Testing
    Lenvatinib plus SIRT, Lenvatinib
    Where
    China
    Volunteers
    78 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06904196
  • Severe Pneumonia

    Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia(the HSV-SP Study)

    • Not yet recruiting
    • Age: 18 to 100 years
    • Observational study

    Severe pneumonia(SP) is a one of the main causes of death for critically ill patients.Samples of bronchoalveolar lavage fluid (BALF) from SP patients often report positive for herpes simplex virus type 1 (HSV-1) DNA.

    Trial name
    NCT06936683
    Testing
    Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy, throat Swab
    Volunteers
    323 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06936683
  • Hepatocellular Carcinoma Non-resectable

    DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

    • Recruiting
    • Age: 18 to 75 years
    • Phase 2

    This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…

    Trial name
    NCT06397235
    Testing
    DEB-TACE+HAIC, DEB-TACE
    Where
    China
    Volunteers
    130 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06397235
  • Hepatocellular Carcinoma Non-resectable

    Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT

    • Recruiting
    • Age: 18 to 75 years
    • Phase 3

    This study is conducted to evaluate the efficacy and safety of lenvatinib plus transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX regemen…

    Trial name
    NCT06492395
    Testing
    Len+DEB-TACE+HAIC, Len+DEB-TACE
    Where
    China
    Volunteers
    178 people
    Sponsor
    Second Affiliated Hospital of Guangzhou Medical University
    Can I take part? NCT06492395

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in